REGENXBIO Inc.
NASDAQ: RGNX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Curran Simpson
- Employees
- 353
- Headquarters
- Rockville, United States
- IPO year
- 2015
- Market cap
- $515.4M
- Website
- https://www.regenxbio.com
Loading RGNX…
Loading profile data…Frequently asked questions about RGNX
What does REGENXBIO Inc. (RGNX) do?
REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its...
Where does RGNX trade?
REGENXBIO Inc. (RGNX) trades on the NASDAQ Global Select.
What sector is RGNX in?
REGENXBIO Inc. (RGNX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of REGENXBIO Inc.?
Curran Simpson is the chief executive officer of REGENXBIO Inc. (RGNX).
Where is REGENXBIO Inc. headquartered?
REGENXBIO Inc. is headquartered in United States.
Does RGNX pay a dividend?
REGENXBIO Inc. (RGNX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did RGNX go public?
REGENXBIO Inc. (RGNX) completed its initial public offering in 2015.